The ALS Association today announced $ 1 million funding in support of a Phase II clinical trial investigating anti-inflammatory effects of RNS60 in ALS patients. The funding is provided by the ALS association partnership with ALS Finding a Cure and the Northeast ALS Consortium (NEALS). The multicenter, randomized, placebo controlled study targets enrollment of 142 ALS patients in 20 clinical centers in Italy and at Massachusetts General Hospital (MGH) in the U.S.

To read the full press release, click here: http://www.alsa.org/news/media/press-releases/rns60-treatment-120216.html